Amend W J, Gjertson D W, Cecka J M
UCLA Tissue Typing Laboratory, Los Angeles, California, USA.
Clin Transpl. 1995:395-404.
Many patients receiving primary cadaver renal transplants have complications in their early post-transplant courses which can affect and possibly confound long-term outcome analyses. Forty-four percent of primary cadaver recipients in the present study were excluded because of early events: delayed graft function (DGF) and early rejection episodes (ERE). Even with these exclusions, similar conclusions to the previous study (1) were noted: that is, the patients with systemic diseases (NS, HTN and IDDM) had the lowest 5-year graft survivals (57-62%) compared to those with diseases that were primarily renal (ALP, IGA and PC) which had better 5-year graft survival results (76-81%). Long-term half-life calculations also demonstrated improved graft survival prognoses in patients with primarily renal diseases (15-18 years in ALP, IGA and PC vs 6-8 years in IDDM, HTN and NS). Again, with the exclusions of patients with early events, Black recipients with HTN did not fare as well as non-Blacks (5-year graft survival of only 52% vs 69%). Many long-term graft losses were due to deaths, oftentimes from cardiovascular diseases. This was especially prominent in disease states with the greatest potential for arteriosclerosis (IDDM, HTN and NS). When patients with early events were excluded, the percent of graft losses attributable to patient death ranged from 21-58%, but were the highest with HTN, PC (age related) and IDDM: 41%, 45% and 58%. A similar analysis in IDDM patients receiving either a LD, SPK or KAT-type transplant revealed that although there was a 10% reduction in 5-year graft survival for KAT patients, most of these graft losses were owing to patient death. Outcomes in SPK and LD in IDDM patients were similar, suggesting selection bias and center effects with the latter two types of transplants going to healthier IDDM patients. It is too soon to conclude whether FK506 has a particularly beneficial role in one primary disease or another as compared to CsA. Combined kidney transplantation with a liver or heart transplant appears to be a reasonable risk. When graft losses due to patient deaths are accounted for, kidney graft survival was approximately that of kidney alone transplantation, suggesting again that graft loss due to patient death must be accounted for when analyzing transplant graft survival.
许多接受初次尸体肾移植的患者在移植后的早期病程中会出现并发症,这些并发症可能会影响并可能混淆长期预后分析。在本研究中,44%的初次尸体肾移植受者因早期事件被排除在外:移植肾功能延迟(DGF)和早期排斥反应(ERE)。即使排除了这些患者,仍得出了与先前研究(1)相似的结论:即,患有全身性疾病(NS、HTN和IDDM)的患者5年移植肾存活率最低(57%-62%),而主要患有肾脏疾病(ALP、IGA和PC)的患者5年移植肾存活率更高(76%-81%)。长期半衰期计算也表明,主要患有肾脏疾病的患者移植肾存活预后更好(ALP、IGA和PC患者为15-18年,而IDDM、HTN和NS患者为6-8年)。同样,排除早期事件患者后,患有HTN的黑人受者的情况不如非黑人受者(5年移植肾存活率仅为52%,而非黑人受者为69%)。许多长期移植肾丢失是由于死亡,通常是死于心血管疾病。这在具有最大动脉硬化潜力的疾病状态(IDDM、HTN和NS)中尤为突出。当排除早期事件患者后,因患者死亡导致的移植肾丢失百分比在21%-58%之间,但在HTN、PC(与年龄相关)和IDDM患者中最高:分别为41%、45%和58%。对接受LD、SPK或KAT型移植的IDDM患者进行的类似分析表明,尽管KAT患者的5年移植肾存活率降低了10%,但这些移植肾丢失大多是由于患者死亡。IDDM患者接受SPK和LD移植的结果相似,这表明后两种类型的移植存在选择偏倚和中心效应,即选择了更健康的IDDM患者。与环孢素(CsA)相比,目前尚无法确定FK506在某一种原发性疾病中是否具有特别有益的作用。联合肾移植与肝移植或心脏移植似乎是一种合理的选择。当考虑因患者死亡导致的移植肾丢失时,肾移植存活率与单独肾移植大致相同,这再次表明在分析移植肾存活情况时必须考虑因患者死亡导致的移植肾丢失。